Epcoritamab plus R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data

L Falchi; MR Clausen; F Offner; S de Vos; J Brody; KM Linton; S Snauwaert; R Cordoba; J Wu; I Bykhovski; A Rana; D Belada

doi:10.1016/S2152-2650(23)01319-8

Epcoritamab plus R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data

L Falchi, MR Clausen, F Offner, S de Vos, J Brody, KM Linton, S Snauwaert, R Cordoba, J Wu, I Bykhovski, A Rana, D Belada

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S431-S432
Number of pages	2
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	23
DOIs	https://doi.org/10.1016/S2152-2650(23)01319-8
Publication status	Published - Sept 2023

Keywords

ABCL
Phase II
Bispecific
Diffuse large B-cell lymphoma
Hematologic malignancy
Non-Hodgkin lymphoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2152-2650(23)01319-8

Cite this

Falchi, L., Clausen, MR., Offner, F., de Vos, S., Brody, J., Linton, KM., Snauwaert, S., Cordoba, R., Wu, J., Bykhovski, I., Rana, A., & Belada, D. (2023). Epcoritamab plus R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data. Clinical Lymphoma, Myeloma and Leukemia, 23, S431-S432. https://doi.org/10.1016/S2152-2650(23)01319-8

@article{5dbfc9bef4804324977748d83772e631,

title = "Epcoritamab plus R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data",

keywords = "ABCL, Phase II, Bispecific, Diffuse large B-cell lymphoma, Hematologic malignancy, Non-Hodgkin lymphoma",

author = "L Falchi and MR Clausen and F Offner and {de Vos}, S and J Brody and KM Linton and S Snauwaert and R Cordoba and J Wu and I Bykhovski and A Rana and D Belada",

year = "2023",

month = sep,

doi = "10.1016/S2152-2650(23)01319-8",

language = "English",

volume = "23",

pages = "S431--S432",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier BV",

}

Falchi, L, Clausen, MR, Offner, F, de Vos, S, Brody, J, Linton, KM, Snauwaert, S, Cordoba, R, Wu, J, Bykhovski, I, Rana, A & Belada, D 2023, 'Epcoritamab plus R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data', Clinical Lymphoma, Myeloma and Leukemia, vol. 23, pp. S431-S432. https://doi.org/10.1016/S2152-2650(23)01319-8

Epcoritamab plus R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data. / Falchi, L; Clausen, MR; Offner, F et al.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, 09.2023, p. S431-S432.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Epcoritamab plus R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma

T2 - Updated EPCORE NHL-2 Data

AU - Falchi, L

AU - Clausen, MR

AU - Offner, F

AU - de Vos, S

AU - Brody, J

AU - Linton, KM

AU - Snauwaert, S

AU - Cordoba, R

AU - Wu, J

AU - Bykhovski, I

AU - Rana, A

AU - Belada, D

PY - 2023/9

Y1 - 2023/9

KW - ABCL

KW - Phase II

KW - Bispecific

KW - Diffuse large B-cell lymphoma

KW - Hematologic malignancy

KW - Non-Hodgkin lymphoma

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001062479600452&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/S2152-2650(23)01319-8

DO - 10.1016/S2152-2650(23)01319-8

M3 - Meeting Abstract

SN - 2152-2650

VL - 23

SP - S431-S432

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

ER -

Epcoritamab plus R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data

Keywords

UN SDGs

Access to Document

Other files and links

Cite this